Program
23-valent pneumococcal capsular polysaccharide vaccine
Also written as “PPV23”, “23-valent pneumococcal polysaccharide vaccine” and “Pneumovax™ 23”.
Its studies are mostly in Pneumococcal Infections · Influenza, Human · Diphtheria · Pneumonia, Pneumococcal · Whooping Cough, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 50 open or running | phase 4since Oct 6, 2014 | Jul 3, 2007 | none ahead |
| GlaxoSmithKline | 40 open or running | phase 4since Feb 20, 2014 | Mar 24, 2006 | none ahead |
| Sinopharm | 20 open or running | phase 4since Jan 6, 2021 | Jan 6, 2021 | none ahead |
| Aimei Vacin BioPharm (Zhejiang) | 11 open or running | phase 3since Sep 13, 2023 | Sep 13, 2023 | none ahead |
| Chongqing Zhifei Biological Products | 10 open or running | phase 3since Feb 18, 2020 | Feb 18, 2020 | none ahead |
| Pfizer | 10 open or running | phase 4since Aug 21, 2006 | Aug 21, 2006 | none ahead |
| Sanofi | 10 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Sinovac Biotech | 10 open or running | phase 4since Jul 13, 2022 | Jul 13, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Mar 24, 2006.
- Aug 21, 2006Pfizer’s first study: phase 4 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT00368186 · 51 enrolled · France
- Jul 3, 2007Merck’s first study: phase 3 study in Pneumococcal InfectionsNew to MerckMerck · NCT00496093 · 133 enrolled
- Sep 21, 2007Phase 3 study in Herpes ZosterMerck · NCT00535730 · 473 enrolled
- Dec 19, 2007Sanofi’s first study: phase 3 study in Streptococcus PneumoniaeNew to SanofiSanofi · NCT00594347 · 339 enrolled · Thailand
- Nov 21, 2012Phase 3 study in Pneumococcal InfectionsMerck · NCT01734239 · 102 enrolled
- Feb 20, 2014Phase 4 study in Whooping CoughGlaxoSmithKline · NCT02072525 · 359 enrolled · Canada
- Aug 14, 2014Phase 3 study in Influenza, HumanGlaxoSmithKline · NCT02218697 · 357 enrolled · Belgium, France
- Aug 22, 2014Phase 3 study in Pneumococcal InfectionsMerck · NCT02225587 · 400 enrolled
- Oct 6, 2014Phase 4 study in Pneumococcal InfectionsMerck · NCT02260882 · 243 enrolled
- Feb 9, 2020Phase 1 study in Healthy VolunteersGlaxoSmithKline · NCT04265911 · 126 enrolled · Japan
- Feb 18, 2020Chongqing Zhifei Biological Products’ first study: phase 3 study in Pneumonia, PneumococcalNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT04278248 · 1,940 enrolled · China
- Jan 6, 2021Sinopharm’s first studies: 2 phase 4 studies in VaccinationNew to SinopharmSinopharm · NCT04701788, NCT04700618
- Jul 13, 2022Sinovac Biotech’s first study: phase 4 study in Influenza, HumanNew to Sinovac BiotechSinovac Biotech · NCT05471531 · 3,000 enrolled · China
- Sep 13, 2023Aimei Vacin BioPharm (Zhejiang)’s first study: phase 3 study in Pneumococcal InfectionsNew to Aimei Vacin BioPharm (Zhejiang)Aimei Vacin BioPharm (Zhejiang) · NCT06044077 · 1,920 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06044077Pneumococcal Infections · China | 3 | Recruiting | Aimei Vacin BioPharm (Zhejiang) | Mar 8, 2024 | 1,920 |
| NCT05471531Influenza, Human · China | 4 | Completed | Sinovac Biotech | Mar 10, 2022 | 3,000 |
| NCT04701788Vaccination · China | 4 | Completed | Sinopharm | Dec 20, 2021 | 331 |
| NCT04700618Vaccination · China | 4 | Completed | Sinopharm | Aug 22, 2021 | 330 |
| NCT04278248Pneumonia, Pneumococcal · China | 3 | Completed | Chongqing Zhifei Biological Products | Jun 7, 2018 | 1,940 |
| NCT04265911Healthy Volunteers · Japan | 1 | Completed | GlaxoSmithKline | Nov 7, 2020 | 126 |
| NCT02260882Pneumococcal Infections | 4 | Completed | Merck | Apr 9, 2015 | 243 |
| NCT02225587Pneumococcal Infections | 3 | Completed | Merck | Jul 6, 2015 | 400 |
| NCT02218697Influenza, Human · Belgium, France | 3 | Completed | GlaxoSmithKline | Jan 14, 2015 | 357 |
| NCT02072525Whooping Cough · Canada | 4 | Completed | GlaxoSmithKline | Jun 2, 2015 | 359 |
| NCT01734239Pneumococcal Infections | 3 | Completed | Merck | Oct 22, 2013 | 102 |
| NCT00594347Streptococcus Pneumoniae · Thailand | 3 | Completed | Sanofi | Mar 2008 | 339 |
| NCT00535730Herpes Zoster | 3 | Completed | Merck | Feb 2008 | 473 |
| NCT00496093Pneumococcal Infections | 3 | Completed | Merck | Jan 2006 | 133 |
| NCT00368186Pneumococcal Infections · France | 4 | Terminated | Pfizer | 51 | |
| NCT00307008Pneumonia · Sweden | 2 | Completed | GlaxoSmithKline | Feb 2005 | 1,198 |
How it is read
Names in the registry
- “PPV23”, 3 entries
- “23-valent pneumococcal polysaccharide vaccine”, 3 entries
- “Pneumovax™ 23”, 3 entries
- “Pneumo 23”, 2 entries
- “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 6 studies
- Influenza, Human, 2 studies
- Diphtheria, 1 study
- Pneumonia, Pneumococcal, 1 study
- Whooping Cough, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.